Search details
1.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Lancet Healthy Longev
; 5(3): e182-e193, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38432247
Results
1 -
1
de 1
1
Next >
>>